Orforglipron is a once-daily pill that activates the glucagon-like peptide-1 (GLP-1) receptor, the same target as semaglutide. Unlike semaglutide, liraglutide or tirzepatide, it is not a peptide. It is a small synthetic molecule, discovered at Chugai Pharmaceutical and developed by Eli Lilly (Kawai et al., PNAS 2020), that survives the gut and is absorbed like an ordinary tablet drug.
The FDA approved it on April 1, 2026 as Foundayo, for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition (FDA approval letter). Unlike oral semaglutide, it can be taken at any time of day, with or without food. Lilly has also submitted it to the FDA for type 2 diabetes; that use is not approved yet.
This page summarizes what the FDA label and the phase 3 ATTAIN (weight) and ACHIEVE (diabetes) trials report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Drug class | Non-peptide (small-molecule) GLP-1 receptor agonist |
| Brand / approval | Foundayo (Eli Lilly), NDA 220934; FDA approved April 1, 2026 |
| Approved use (US) | Weight reduction and long-term maintenance in adults with obesity, or overweight plus a weight-related condition |
| Route | Oral tablet, once daily, with or without food |
| Strengths | 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg |
| Labeled dose | Start 0.8 mg/day; step up every 30 days or more; maintenance 5.5–17.2 mg/day; maximum 17.2 mg/day |
| Half-life (label) | About 29–49 h; steady state after about 1 week |
| Oral bioavailability (label) | 77% (vs 0.4–1% for Rybelsus semaglutide tablets) |
| Metabolism | Mainly liver CYP3A4, so strong CYP3A4 inhibitors and inducers change its levels |
| WADA | Not named on the 2026 Prohibited List |
What it is
Orforglipron (research codes LY3502970 and OWL833) is a synthetic organic molecule, not a modified hormone. The marketed drug is the calcium salt, formula C₄₈H₄₇F₂N₁₀O₅·½Ca, molecular weight 902.0 g/mol (Foundayo label).
The discovery paper described it as a partial agonist at the GLP-1 receptor. It is biased toward G-protein signaling over β-arrestin recruitment, and it binds a distinctive pocket in the upper part of the receptor (the upper helical bundle) (Kawai et al., PNAS 2020). Its binding depends on an amino acid found only in the primate receptor (Trp33). As a result:
- it is active at the human and monkey GLP-1 receptor;
- it is not pharmacologically active in rats, mice or rabbits, which shapes how its animal safety data must be read (see the thyroid section below);
- in humanized transgenic mice and in monkeys, oral dosing lowered glucose and food intake with effects comparable to injectable exenatide (animal data).
How it compares with semaglutide and tirzepatide
The peptide GLP-1 drugs are made from amino acids and are digested in the gut. Oral semaglutide only works because of an absorption enhancer, and even then very little reaches the blood. Orforglipron sidesteps this problem by not being a peptide at all.
| Feature | Orforglipron (Foundayo) | Oral semaglutide (Rybelsus) | Tirzepatide (Zepbound) |
|---|---|---|---|
| Molecule | Small molecule | Peptide | Peptide |
| Receptor targets | GLP-1 | GLP-1 | GIP and GLP-1 |
| Route and frequency | Tablet, once daily | Tablet, once daily | Injection, once weekly |
| Food and water rules | None: any time, with or without food | Empty stomach with up to 4 oz of water; wait at least 30 minutes before eating, drinking or other oral drugs | None |
| Absolute bioavailability | 77% | 0.4–1% | Not applicable (injected) |
| Elimination half-life | About 29–49 h | About 1 week | About 5–6 days |
Sources: Foundayo label; Rybelsus / oral Ozempic label; Zepbound label. For the injectable and oral peptides themselves, see semaglutide, tirzepatide and liraglutide.
Pharmacokinetics
From the Foundayo label (DailyMed):
| Parameter | Value |
|---|---|
| Time to peak | 4–8 h after a dose |
| Absolute bioavailability | 77% (0.8 mg dose) |
| Food effect | Not clinically relevant (AUC −19%, peak −26% with food in a study of an investigational tablet) |
| Plasma protein binding | Over 99% |
| Volume of distribution | About 285 L |
| Clearance | 7.15 L/h |
| Elimination half-life | About 29–49 h |
| Steady state | About 1 week of daily dosing |
| Metabolism | Mainly CYP3A4 in the liver (also a CYP2J2 substrate) |
| Excretion | 87% in feces as metabolites; under 1% in urine |
Two practical consequences stand out:
- Kidney function does not matter much. Severe renal impairment and end-stage kidney disease did not change exposure, and no dose change is labeled.
- The liver does. Exposure (AUC) rose 1.7-fold in moderate and 4.6-fold in severe hepatic impairment. The drug is not recommended in severe hepatic impairment (Child-Pugh C).
Orforglipron also slows stomach emptying. The effect is largest after the first dose and fades with continued use. On the first 0.8 mg dose, it cut the peak level of acetaminophen (a marker of gastric emptying) by 28%.
Label doses vs trial doses
The phase 3 trials used an investigational formulation dosed at 3, 6, 12 and 36 mg. The marketed tablet is a different formulation with different milligram numbers. The label presents trial data “as equivalent dosages” of Foundayo, and Lilly reports the trial doses as the following Foundayo doses (Foundayo label; Lilly, June 2026; Klein et al., Lancet 2026):
| Trial formulation | Foundayo tablet equivalent |
|---|---|
| 3 mg | 2.5 mg |
| 6 mg | 5.5 mg |
| 12 mg | 9 mg |
| 36 mg | 17.2 mg |
The trial descriptions below use the doses as published, with the Foundayo equivalent in brackets where useful.
Approved medical use and regulatory status
Foundayo is approved, together with a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain the reduction long term in adults with:
- obesity; or
- overweight plus at least one weight-related condition.
The label says it should not be combined with another GLP-1 receptor agonist (Foundayo label).
| Labeled step | Dose |
|---|---|
| Start | 0.8 mg once daily for at least 30 days |
| Step 2 | 2.5 mg once daily for at least 30 days |
| Step 3 | 5.5 mg once daily |
| Further steps, if needed and tolerated | 9 mg, 14.5 mg, then 17.2 mg, each after at least 30 days |
| Maximum | 17.2 mg once daily (9 mg with a strong CYP3A4 inhibitor) |
Tablets are swallowed whole, one per day. If 7 or more consecutive doses are missed, the label says to restart the escalation at a lower dose because of the risk of stomach and gut side effects.
Regulatory timeline:
- January 20, 2026. FDA received the new drug application.
- April 1, 2026. FDA approved Foundayo as a new molecular entity for weight management, without an advisory committee (FDA approval letter; Drugs@FDA). Pediatric studies in ages 6–17 were deferred.
- June 2026. Lilly announced it planned to submit Foundayo for type 2 diabetes under the FDA Commissioner’s National Priority Review Voucher program (Lilly, June 2026).
- August 2026. Lilly reported that the US type 2 diabetes submission had been made (Lilly Q2 2026 results). The current label (August 2026) still lists weight management as the only indication.
What the research shows
Phase 2: weight loss in obesity
The dose-finding trial randomized 272 adults with obesity or overweight, without diabetes, to orforglipron 12, 24, 36 or 45 mg or placebo daily for 36 weeks (Wharton et al., NEJM 2023). Mean weight change at week 36 ranged from −9.4% to −14.7% on orforglipron vs −2.3% on placebo. Gastrointestinal effects led 10–17% of orforglipron participants to stop.
ATTAIN-1: obesity without diabetes
ATTAIN-1 was a 72-week, double-blind trial in 3,127 adults with obesity, or overweight plus a weight-related condition, and no diabetes. Mean baseline weight was 103.2 kg and BMI 37 (Wharton et al., NEJM 2025). Results as presented in the label (Trial 1; all randomized patients):
| Outcome at week 72 | Placebo | 6 mg [5.5 mg] | 12 mg [9 mg] | 36 mg [17.2 mg] |
|---|---|---|---|---|
| Patients randomized | 949 | 723 | 725 | 730 |
| Mean weight change | −2.1% | −7.4% | −8.3% | −11.1% |
| Difference from placebo (95% CI) | — | −5.3 (−6.1 to −4.4) | −6.2 (−7.1 to −5.3) | −9.0 (−10.0 to −8.1) |
| Lost at least 10% | 13.0% | 32.5% | 39.8% | 54.5% |
| Lost at least 15% | 6.0% | 14.3% | 20.1% | 35.9% |
| Lost at least 20% | 2.9% | 5.9% | 8.9% | 18.4% |
| Waist circumference | −3.1 cm | −7.0 cm | −8.2 cm | −10.0 cm |
| Systolic blood pressure | −1.4 mm Hg | −5.7 mm Hg | −5.1 mm Hg | −6.4 mm Hg |
| Triglycerides | −4.0% | −10.4% | −13.1% | −20.0% |
The NEJM paper reported essentially the same figures (−11.2% at 36 mg vs −2.1% on placebo). Treatment was stopped because of adverse events by 5.3–10.3% of orforglipron patients vs 2.7% on placebo.
ATTAIN-2: obesity with type 2 diabetes
ATTAIN-2 randomized 1,613 adults with BMI of 27 or more and type 2 diabetes (HbA1c 7–10%) to 6, 12 or 36 mg or placebo for 72 weeks (Horn et al., Lancet 2025). Weight loss was smaller than in ATTAIN-1, where people did not have diabetes:
| Outcome at week 72 | Placebo | 6 mg [5.5 mg] | 12 mg [9 mg] | 36 mg [17.2 mg] |
|---|---|---|---|---|
| Mean weight change | −2.5% | −5.1% | −7.0% | −9.6% |
| Difference from placebo (95% CI) | — | −2.7 (−3.7 to −1.6) | −4.5 (−5.5 to −3.6) | −7.1 (−8.2 to −6.1) |
| HbA1c change (label) | −0.4 | −1.2 | −1.4 | −1.7 |
| Lost at least 10% (label) | 9.2% | 22.5% | 31.1% | 45.6% |
HbA1c is the average blood sugar over about three months, measured in percentage points; the HbA1c and responder rows come from the Foundayo label. Discontinuation for adverse events was 6.1–9.9% with orforglipron vs 4.1% with placebo.
ATTAIN-MAINTAIN: switching from injections to the pill
This phase 3b trial took people who had already lost weight on weekly tirzepatide (205 people) or semaglutide (171 people) in the SURMOUNT-5 study. They were randomized to daily orforglipron or placebo for 52 weeks (Aronne et al., Nat Med 2026):
| Prior injectable | Share of earlier weight loss kept: orforglipron | Share kept: placebo | Difference (95% CI) |
|---|---|---|---|
| Tirzepatide | 74.7% | 49.2% | 25.5 points (14.5–36.5) |
| Semaglutide | 79.3% | 37.6% | 41.7 points (24.4–59.0) |
So most, but not all, of the injectable-driven loss was kept after switching. The trial had no arm that stayed on the injection, and it lasted only one year.
Body composition
The label states that orforglipron reduces body weight “with greater fat mass loss than lean mass loss” (Foundayo label). In other words, some lean mass is lost too, as with all diet- and drug-induced weight loss. Detailed body-composition figures were not available in the sources reviewed for this page.
ACHIEVE trials: type 2 diabetes
The ACHIEVE program tested orforglipron for blood sugar control. All were phase 3 randomized trials; the primary outcome was change in HbA1c.
| Trial | Design | Doses | HbA1c change | Comparator | Weight change |
|---|---|---|---|---|---|
| ACHIEVE-1 (Rosenstock et al., NEJM 2025) | 559 adults, early diabetes on diet and exercise only; 40 weeks; vs placebo | 3, 12, 36 mg | −1.24, −1.47, −1.48 | Placebo −0.41 | −4.5%, −5.8%, −7.6% vs −1.7% |
| ACHIEVE-2 (Welch et al., Lancet 2026) | 962 adults on metformin; 40 weeks; open label vs dapagliflozin 10 mg | 3, 12, 36 mg | −1.23, −1.50, −1.56 | Dapagliflozin −0.81 | Not in abstract |
| ACHIEVE-3 (Rosenstock et al., Lancet 2026) | 1,698 adults on metformin; 52 weeks; open label vs oral semaglutide | 12, 36 mg | −1.71, −1.91 | Semaglutide 7 mg −1.23; 14 mg −1.47 | See below |
| ACHIEVE-5 (Giorgino et al., JAMA 2026) | 546 adults on titrated insulin glargine; 40 weeks; vs placebo | 3, 12, 36 mg | −1.58, −1.88, −1.82 | Placebo −0.79 | −2.6%, −4.8%, −5.4% vs +0.2% |
All orforglipron doses beat placebo, and all were non-inferior and then superior to dapagliflozin. ACHIEVE-1 reported no severe hypoglycemia (dangerously low blood sugar needing help from another person), and ACHIEVE-5 found no increase in clinically significant hypoglycemia vs placebo, even on top of insulin.
Head to head with oral semaglutide (ACHIEVE-3)
ACHIEVE-3 is the only direct comparison with another oral GLP-1 drug. It compared orforglipron 12 mg [9 mg] and 36 mg [17.2 mg] with Rybelsus-type oral semaglutide 7 mg and 14 mg in adults with type 2 diabetes on metformin. Baseline HbA1c was 8.3% (Rosenstock et al., Lancet 2026).
| Comparison | HbA1c difference (95% CI) |
|---|---|
| Orforglipron 12 mg vs semaglutide 7 mg | −0.48 (−0.65 to −0.31) |
| Orforglipron 36 mg vs semaglutide 14 mg | −0.44 (−0.62 to −0.26) |
| Orforglipron 12 mg vs semaglutide 14 mg | −0.24 (−0.41 to −0.07) |
Both orforglipron doses were superior to both semaglutide doses for HbA1c. Lilly reported weight change at week 52 under the “efficacy estimand,” which counts only people who stayed on treatment (Lilly, June 2026):
| Arm | Weight change at week 52 |
|---|---|
| Oral semaglutide 7 mg | −3.7% |
| Oral semaglutide 14 mg | −5.3% |
| Orforglipron 12 mg [9 mg] | −6.7% |
| Orforglipron 36 mg [17.2 mg] | −9.2% |
The trade-off was tolerability. Gastrointestinal adverse events occurred in 58–59% on orforglipron vs 37–45% on semaglutide. Discontinuation for adverse events was 9–10% vs 4–5%, and pulse rose by 3.7–4.7 vs 1.0–1.5 beats per minute. The trial was open label and funded by Lilly, and it compared only the 7 mg and 14 mg diabetes doses of oral semaglutide.
Cardiovascular safety (ACHIEVE-4)
ACHIEVE-4 randomized 2,749 adults with type 2 diabetes and established cardiovascular or chronic kidney disease to orforglipron (up to 36 mg [17.2 mg]) or insulin glargine. Median follow-up was 2 years (Klein et al., Lancet 2026).
| Outcome | Orforglipron | Insulin glargine |
|---|---|---|
| MACE-4 (cardiovascular death, heart attack, stroke or hospitalization for unstable angina) | 4.2% | 5.0% |
| Hazard ratio (95% CI) | 0.84 (0.59–1.20) | — |
| Clinically significant or severe hypoglycemia | 6.8% | 19.2% |
| Gastrointestinal adverse events | 62.1% | 14.2% |
| Deaths | 1.4% | 3.2% |
The trial was designed to show non-inferiority (that orforglipron is not meaningfully worse), and it did. It was not designed to prove a cardiovascular benefit, and the hazard ratio’s confidence interval includes no difference. As the trial authors note, some peptide GLP-1 drugs (see semaglutide) have established cardiovascular benefit; orforglipron has not shown one yet.
Side effects and risks
Boxed warning: thyroid C-cell tumors
Foundayo carries the GLP-1 class boxed warning, with a twist. Peptide GLP-1 drugs cause thyroid C-cell tumors in rats and mice. Orforglipron is not active at the rodent receptor, and a 2-year rat study and a 26-week transgenic mouse study found no tumors. That result says little about risk, because the drug cannot act on the rodent receptor in the first place (Foundayo label).
The label therefore keeps the contraindication in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). The human relevance of the rodent findings is not known.
Gastrointestinal effects
Stomach and gut effects are the main side effects. They were most common during dose escalation and eased over time. In the pooled ATTAIN-1 and ATTAIN-2 data (3,155 patients on orforglipron), the label reports:
| Adverse reaction | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Nausea | 10% | 26% | 34% | 35% |
| Constipation | 9% | 20% | 27% | 24% |
| Diarrhea | 11% | 21% | 23% | 25% |
| Vomiting | 4% | 13% | 21% | 24% |
| Dyspepsia (indigestion) | 4% | 12% | 16% | 13% |
| Abdominal pain | 7% | 13% | 14% | 14% |
| Any GI adverse reaction | 37% | 60% | 68% | 69% |
| Stopped because of GI effects | 0.7% | 3% | 6% | 6% |
Severe GI reactions occurred in about 3% vs 1% on placebo. The label does not recommend Foundayo for people with severe gastroparesis (very slow stomach emptying). Dehydration from vomiting or diarrhea can cause acute kidney injury, reported in 0.2% vs 0.05% on placebo.
Pancreas and gallbladder
- Pancreatitis. Adjudicated acute pancreatitis occurred in 6 orforglipron patients (0.14 per 100 patient-years) vs 1 placebo patient (0.04 per 100 patient-years). Lipase rose by 26–31% and amylase by 16–20% on average, of uncertain meaning without symptoms.
- Gallbladder. Gallstones occurred in 1% vs 0.7%, and acute cholecystitis (gallbladder inflammation) in 0.4% vs 0.3%. These events were linked to weight loss.
Heart rate and blood pressure
Heart rate rose by 4–5 beats per minute on average vs 0.5 on placebo. Tachycardia (fast heart rate) was reported in 3% vs 0.9%. Hypotension (low blood pressure) occurred in 2% vs 0.5%, and in 4% of those also taking blood pressure medicines.
Hypoglycemia
In ATTAIN-2 (people with diabetes), glucose under 54 mg/dL occurred in 2% on orforglipron vs 0.2% on placebo. It occurred in 7% of those also taking a sulfonylurea vs 0.5% of those not taking one. The label advises considering a lower insulin or sulfonylurea dose when starting.
Liver
Because orforglipron is a small molecule cleared by the liver, liver safety was watched closely. A Lilly-funded pooled analysis of seven phase 3 trials (6,920 people on orforglipron) found no cases of drug-induced liver injury meeting Hy’s Law criteria (a standard screen for serious drug liver injury). ALT and AST fell on average, in line with weight loss (Wharton et al., Diabetes Obes Metab 2026). Longer real-world use is still needed.
Other effects
The label also reports these effects in the pooled weight trials:
- Hair loss: 7% of women vs 0.9% of men on orforglipron, linked to weight loss.
- Dysesthesia (abnormal skin sensations): 1% at 17.2 mg.
- Hypersensitivity reactions: 0.5% vs 0.3% on placebo.
- Diabetic retinopathy: rapid glucose lowering can temporarily worsen it; those with a history of retinopathy should be monitored.
- Aspiration under anesthesia: because the stomach empties slowly, food can remain at the time of surgery or deep sedation.
Interactions
Because orforglipron depends on CYP3A4, drug interactions matter more than with the peptide GLP-1 drugs (Foundayo label):
| Other drug | Effect on orforglipron or the other drug | Label action |
|---|---|---|
| Clarithromycin (strong CYP3A4 inhibitor) | Orforglipron AUC ↑3.5-fold | Maximum 9 mg/day |
| Strong CYP3A4 + OATP1B inhibitors (e.g., ritonavir) | Large rise expected | Avoid |
| Carbamazepine (strong CYP3A4 inducer) | Orforglipron AUC ↓82% | Avoid |
| Efavirenz (moderate inducer, modeled) | Orforglipron AUC ↓61% | Monitor; escalate dose if needed |
| Simvastatin | Active simvastatin acid ↑2–2.5-fold | Do not exceed simvastatin 20 mg/day |
| Insulin or sulfonylureas | More hypoglycemia | Consider a lower dose of these |
| Oral contraceptives | Absorption may fall during slowed gastric emptying | Use a non-oral method or add a barrier method for 30 days after starting and after each dose increase |
Who should not use it
- People with a personal or family history of MTC, or with MEN 2.
- People with a known serious allergy to orforglipron or its ingredients.
- Pregnancy: stop when pregnancy is recognized. Weight loss offers no benefit in pregnancy. Animal data are limited because the drug is inactive in rats and rabbits.
- Breastfeeding: not recommended. The drug reached rat milk at three times plasma levels.
- Severe hepatic impairment (Child-Pugh C): not recommended.
- Children: safety and effectiveness not established.
Key takeaways
- A GLP-1 drug that is not a peptide. Orforglipron is a small molecule with 77% oral bioavailability. It needs none of the fasting rules that oral semaglutide does.
- Approved for weight management in the US. FDA approved Foundayo on April 1, 2026. A type 2 diabetes application was submitted in 2026 but is not yet approved.
- Moderate, dose-dependent weight loss. At the top dose, ATTAIN-1 showed about 11% mean weight loss at 72 weeks (9% more than placebo). In people with diabetes the figure was about 10%.
- Better than oral semaglutide in a direct diabetes trial, at a tolerability cost. In ACHIEVE-3, both orforglipron doses lowered HbA1c and weight more than Rybelsus doses but caused more GI effects and discontinuations.
- Cardiovascular safety shown, benefit not yet. ACHIEVE-4 showed non-inferiority to insulin glargine for major cardiovascular events.
- Watch drug interactions. As a CYP3A4 substrate, it is affected by strong inhibitors and inducers, and it doubles active simvastatin levels.
Sources
- Eli Lilly and Company. Foundayo (orforglipron) tablets, prescribing information, revised August 2026 (NDA 220934/S-003). DailyMed; FDA.
- Food and Drug Administration. NDA 220934 approval letter, Foundayo (orforglipron) tablets. April 1, 2026. FDA; Drugs@FDA.
- Kawai T, Sun B, Yoshino H, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A. 2020;117(47):29959–29967. PubMed.
- Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877–888. PubMed.
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796–1806. PubMed.
- Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927–2944. PubMed.
- Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679–2687. PubMed.
- Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med. 2025;393(11):1065–1076. PubMed.
- Welch M, Forst T, Jia W, et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial. Lancet. 2026;408(10550):125–140. PubMed.
- Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147–1160. PubMed.
- Giorgino F, D’Souza S, Ludwig L, et al. Orforglipron added to titrated insulin glargine in type 2 diabetes: the ACHIEVE-5 randomized clinical trial. JAMA. 2026;336(5):389–399. PubMed.
- Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. Published online September 30, 2026. PubMed.
- Wharton S, Stefanski A, Chen J, et al. Hepatic safety of orforglipron in adults with obesity or overweight and/or type 2 diabetes: a pooled analysis of the orforglipron phase 3 clinical trials. Diabetes Obes Metab. 2026;28(9):8347–8358. PubMed.
- Eli Lilly and Company. Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials. Press release, June 8, 2026. PR Newswire.
- Eli Lilly and Company. Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress. Press release, August 5, 2026. BioSpace.
- Novo Nordisk. Rybelsus and Ozempic (semaglutide) tablets, prescribing information. DailyMed.
- Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information. DailyMed.
- World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 Prohibited List.